There are increasing problems with cardiotoxicity of anti-cancer drugs [25,34], including those which target the ERK1/2 cascade at the level of MKK1/2 (e.g. trametinib, cobimetinib and selumetinib). The gene discussed is MAP2K1; the disease is cancer.